logo

Gossamer Bio Inc. (GOSS)



Trade GOSS now with
  Date
  Headline
12/6/2022 7:20:39 AM Gossamer Bio : Seralutinib Meets Primary Endpoint In Phase 2 TORREY Study In Pulmonary Arterial Hypertension
9/19/2022 5:07:46 PM Wedbush Starts Gossamer Bio Inc. (GOSS) At Outperform With $24 Price Target
8/9/2022 8:05:24 AM Gossamer Bio Q2 Net Loss $56.5 Mln Or $0.74/shr Vs Net Loss Of $59.8 Mln Or $0.80/shr Prior Year
7/13/2022 7:18:41 AM Gossamer Bio Agrees To Sell About 16.6 Mln Shares In A Private Placement At $7.21/Shr
4/25/2022 7:44:27 AM Gossamer Bio Says GB004 Phase 2 SHIFT-UC Study Did Not Meet Primary Or Secondary Endpoints At Week 12
9/27/2021 10:46:40 AM Gossamer Bio Shares Jump 15%
9/21/2021 8:35:48 AM Gossamer Bio Announces Appointment Of Bryan Giraudo As COO, In Addition To CFO Role
6/21/2021 4:09:31 PM Gossamer Bio Promotes Richard Aranda To Chief Medical Officer